GlassScriptPhysician profile
Benoy Varghese
NPI 1447694252
$3,153.04
in general payments reported to CMS, 2019-2025
31 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $266 · 2021: $546 · 2022: $721 · 2023: $528 · 2024: $407 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.94 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $541.25 | 2020-2025 | Lifevest |
| Abbott Laboratories | $369.10 | 2019-2024 | Jot Dx |
| Boston Scientific Corporation | $302.53 | 2019-2024 | Varithena Administration Pack, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Abiomed | $228.18 | 2024-2025 | Impella |
| Pfizer INC. | $199.35 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $195.00 | 2020-2023 | Xarelto |
| Ge Healthcare | $173.71 | 2020 | |
| Merck Sharp & Dohme LLC | $149.20 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $137.44 | 2024 | |
| Novartis Pharmaceuticals Corporation | $117.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $94.82 | 2020-2023 | Farxiga |
| Medtronic, INC. | $89.34 | 2021-2025 | Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.78 | 2021-2023 | Jardiance |
| Medtronic Vascular, INC. | $58.96 | 2019 | |
| Alnylam Pharmaceuticals INC. | $54.71 | 2021-2023 | Onpattro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53.59 | 2021-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $42.30 | 2021-2022 | |
| Shockwave Medical, INC | $34.06 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $23.23 | 2020 | |
| Medicomp INC | $22.90 | 2022 | |
| Amarin Pharma, INC. | $20.70 | 2020 | |
| Novo Nordisk INC | $18.70 | 2022 | |
| Edwards Lifesciences Corporation | $17.43 | 2021 | |
| Organogenesis INC. | $16.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.47 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $16.35 | 2023 | Inpefa |
| Heartflow, INC. | $16.31 | 2025 | |
| Chiesi USA, INC. | $15.84 | 2024 | Kengreal |
| Cardiovascular Systems INC. | $15.58 | 2019 | |
| Scpharmaceuticals INC. | $15.15 | 2024 | |
| Cardiva Medical, INC. | $14.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benoy Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.